- Home
- SVRA
SVRA
Savara Inc.
as 06-20-2025 4:00pm EST
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 528.3M | IPO Year: | N/A |
| Target Price: | $7.57 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.89 - $5.11 | Next Earning Date: | 08-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Savara Inc. (SVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCracken Joseph S | SVRA | Director | May 29 '25 | Buy | $2.08 | 10,000 | $20,825.00 | 260,837 | |
| RAMSAY DAVID A | SVRA | Director | Mar 31 '25 | Buy | $2.78 | 150,000 | $416,250.00 | 2,513,642 |
Latest Savara Inc. News
SVRA Breaking Stock News: Dive into SVRA Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating
MT Newswires
23 days ago
HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6
MT Newswires
25 days ago
Top Midday Decliners
MT Newswires
25 days ago
Savara Receives FDA Refusal to File Letter for BLA of Potential Autoimmune PAP Therapy; Shares Fall Pre-Bell
Business Wire
25 days ago
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
BioPharma Dive
25 days ago
Biogen strikes RNAi deal with City; Aurion withdraws IPO
Business Wire
a month ago
Savara Announces New Employment Inducement Grant
Business Wire
a month ago
Savara Announces Participation in Jefferies Global Healthcare Conference
Compare SVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SVRA Savara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.